Puzanov Provides Perspective on T-VEC in Melanoma

Source: OncLive, November 2018

In 2015, talimogene laherparepvec (T-VEC; Imlygic) became the first-in-class oncolytic immunotherapy to be FDA approved for the treatment of advanced-stage unresectable melanoma, but its path forward may be in combination with checkpoint inhibitors, explained Igor Puzanov, MD, MSCI, FACP.

In the phase III OPTiM trial, which was the basis for the FDA approval of T-VEC, the therapy significantly extended durable response rates versus subcutaneous GM-CSF.

In a separate phase II study, patients who received the combination of T-VEC and the CTLA-4 inhibitor ipilimumab (Yervoy) experienced a doubling in objective response rate compared with ipilimumab alone (38.7% vs 18.0%; odds ratio [OR], 2.9; 95% CI, 1.5-5.5; P = .002).

read the original full article